G01N 33/6863
Cytokines, i.e. immune system proteins modifying a biological response such as cell
Official title: {Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors}
G01N33/6863 (Cytokines, i.e. immune system proteins modifying a biological response such as cell) appears on 1,698 US grants and 3,155 published applications in this corpus.
Search patents in G01N- Granted patents
- 1,698
- Published applications
- 3,155
- Assignees
- 1,356
- Inventors
- 5,918
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1981 | 2 | 0 |
| 1982 | 1 | 0 |
| 1983 | 1 | 0 |
| 1984 | 1 | 0 |
| 1985 | 2 | 0 |
| 1986 | 2 | 0 |
| 1987 | 9 | 0 |
| 1988 | 7 | 0 |
| 1989 | 4 | 0 |
| 1990 | 4 | 0 |
| 1991 | 4 | 0 |
| 1992 | 7 | 0 |
| 1993 | 3 | 0 |
| 1994 | 14 | 0 |
| 1995 | 6 | 0 |
| 1996 | 16 | 0 |
| 1997 | 18 | 0 |
| 1998 | 40 | 0 |
| 1999 | 30 | 0 |
| 2000 | 22 | 0 |
| 2001 | 33 | 8 |
| 2002 | 24 | 75 |
| 2003 | 25 | 102 |
| 2004 | 25 | 81 |
| 2005 | 29 | 107 |
| 2006 | 49 | 109 |
| 2007 | 43 | 79 |
| 2008 | 49 | 92 |
| 2009 | 45 | 106 |
| 2010 | 68 | 122 |
| 2011 | 61 | 120 |
| 2012 | 52 | 121 |
| 2013 | 66 | 137 |
| 2014 | 54 | 152 |
| 2015 | 75 | 153 |
| 2016 | 64 | 158 |
| 2017 | 98 | 152 |
| 2018 | 83 | 168 |
| 2019 | 77 | 119 |
| 2020 | 90 | 159 |
| 2021 | 80 | 129 |
| 2022 | 74 | 157 |
| 2023 | 69 | 167 |
| 2024 | 60 | 140 |
| 2025 | 63 | 132 |
| 2026 | 49 | 110 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- IFNβ as a pharmacodynamic marker in VSV-IFNβ-NIS oncolytic therapy6 Oct 2026US 12,754,182 B2Mayo Foundation for Medical Education and Research
- Drug-specific pharmacokinetic assay for IL-15 superagonist6 Oct 2026US 12,754,189 B2NantCell, Inc.
- Treatment of autoimmune liver disease15 Sep 2026US 12,736,544 B2The Governors of the University of Alberta
- Controlled release of antibodies to modulate cytokines8 Sep 2026US 12,729,237 B2Flow Pharma, Inc.
- Method for monitoring autoimmune disease8 Sep 2026US 12,730,106 B2The Regents of the University of Micigan
- Composition for inducing immunotolerance8 Oct 2026US 2026/0306540 A1
- Anti-il-13 long-acting nanobody sequence and applications thereof1 Oct 2026US 2026/0297175 A1Shanghai Novamab Biopharmaceuticals Co., Ltd.
- Anti il-11 antibody1 Oct 2026US 2026/0297176 A1
- Patrolling monocyte cellular therapy1 Oct 2026US 2026/0297525 A1New York Blood Center, Inc.
- Methods of treating endometriosis1 Oct 2026US 2026/0298926 A1Cedars-Sinai Medical Center
Most cited
By later US patents
- Interleukin-1α antibodies1,029US 8,034,337 B2Xbiotech, Inc. · 2011
- Patient classification703US 6,763,307 B2Bioseek, Inc. · 2004
- Antibodies to human programmed death receptor PD-1454US 8,354,509 B2MSD Oss B.V. · 2013
- Dye labeled imidazoquinoline compounds201US 6,376,669 B13M Innovative Properties Company · 2002
- Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides190US 5,679,647 AThe Regents of the University of California · 1997